应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
AZN 阿斯利康
未开盘 03-10 16:00:00 EDT
75.99
-1.51
-1.95%
盘后
75.94
-0.05
-0.07%
19:57 EDT
最高
76.97
最低
75.47
成交量
625.47万
今开
76.11
昨收
77.50
日振幅
1.93%
总市值
2,357亿
流通市值
2,348亿
总股本
31.01亿
成交额
4.78亿
换手率
0.20%
流通股本
30.89亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
【欧股“十一罗汉”|诺和诺德跌超8%,阿斯麦跌超4%】周一,阿斯麦控股荷兰阿姆斯特丹股价收跌4.05%,报639.00欧元。诺和诺德哥本哈根股价收跌8.07%,报549.40丹麦克朗,为2023年8月7日以来首次收盘跌穿600整数位心理关口。德国思爱普Sap跌4.78%,阿斯利康跌1.91%,LVMH集团和赛诺菲至多收跌0.69%。罗氏制药、诺华制药、雀巢则至多收涨0.87%,欧莱雅涨1.38%,葛兰素史克涨1.6%。
金融界 · 01:02
【欧股“十一罗汉”|诺和诺德跌超8%,阿斯麦跌超4%】周一,阿斯麦控股荷兰阿姆斯特丹股价收跌4.05%,报639.00欧元。诺和诺德哥本哈根股价收跌8.07%,报549.40丹麦克朗,为2023年8月7日以来首次收盘跌穿600整数位心理关口。德国思爱普Sap跌4.78%,阿斯利康跌1.91%,LVMH集团和赛诺菲至多收跌0.69%。罗氏制药、诺华制药、雀巢则至多收涨0.87%,欧莱雅涨1.38%,葛兰素史克涨1.6%。
阿斯利康PD-L1肿瘤药在中国获批第四项适应证
美港电讯 · 03-10 18:01
阿斯利康PD-L1肿瘤药在中国获批第四项适应证
阿斯利康(AZN.US)胃癌围手术期PD-L1联合疗法优于标准治疗
智通财经 · 03-07
阿斯利康(AZN.US)胃癌围手术期PD-L1联合疗法优于标准治疗
医药生物行业专题:海外制药企业2024Q4&全年业绩回顾
国信证券股份有... · 03-07
医药生物行业专题:海外制药企业2024Q4&全年业绩回顾
【欧股“十一罗汉”|诺和诺德收涨约2.5%,阿斯麦涨超1.8%,雀巢则跌超1.8%】 周三,阿斯麦控股荷兰阿姆斯特丹股价收涨1.85%,报672.70欧元。诺和诺德哥本哈根股价收涨2.48%,报631.50。德国思爱普Sap收涨2.22%,欧莱雅涨1.79%,诺华制药涨0.62%。阿斯利康、罗氏制药、LVMH集团、赛诺菲则收跌0.02%-0.46%,葛兰素史克跌1.72%,雀巢跌1.83%。
金融界 · 03-06
【欧股“十一罗汉”|诺和诺德收涨约2.5%,阿斯麦涨超1.8%,雀巢则跌超1.8%】 周三,阿斯麦控股荷兰阿姆斯特丹股价收涨1.85%,报672.70欧元。诺和诺德哥本哈根股价收涨2.48%,报631.50。德国思爱普Sap收涨2.22%,欧莱雅涨1.79%,诺华制药涨0.62%。阿斯利康、罗氏制药、LVMH集团、赛诺菲则收跌0.02%-0.46%,葛兰素史克跌1.72%,雀巢跌1.83%。
第一三共/阿斯利康(AZN.US)重磅抗体偶联药物(ADC)Enhertu在3期临床试验中获得积极结果
智通财经 · 03-05
第一三共/阿斯利康(AZN.US)重磅抗体偶联药物(ADC)Enhertu在3期临床试验中获得积极结果
阿斯利康(AZN)盘前升1.52% 重度哮喘治疗药物显示积极效果
金吾财讯 · 03-04
阿斯利康(AZN)盘前升1.52% 重度哮喘治疗药物显示积极效果
阿斯利康全球研发(中国)有限公司药品申请临床试验默示许可获受理
金融界 · 03-04
阿斯利康全球研发(中国)有限公司药品申请临床试验默示许可获受理
金十数据整理:每日美股市场要闻速递(3月3日 周一)
美港电讯 · 03-03
金十数据整理:每日美股市场要闻速递(3月3日 周一)
高盛将阿斯利康、诺和诺德、力拓纳入其欧洲“确信名单”。
美港电讯 · 03-03
高盛将阿斯利康、诺和诺德、力拓纳入其欧洲“确信名单”。
第一三共/阿斯利康(AZN.US)重磅ADC疗法有望再获欧盟批准
智通财经 · 03-03
第一三共/阿斯利康(AZN.US)重磅ADC疗法有望再获欧盟批准
金十数据整理:每日美股行情要闻速递(2月27日周四)
美港电讯 · 02-27
金十数据整理:每日美股行情要闻速递(2月27日周四)
阿斯利康(AZN.US)口服小分子疗法3期临床试验结果积极
智通财经 · 02-27
阿斯利康(AZN.US)口服小分子疗法3期临床试验结果积极
【欧股“十一罗汉”|阿斯麦和LVMH集团收涨超2%,诺和诺德跌超2%】周三,阿斯麦控股荷兰阿姆斯特丹股价收涨2.39%,报714.50欧元。诺和诺德哥本哈根股价收跌2.16%,报642.80。LVMH集团涨2.35%,德国思爱普Sap涨1.03%,欧莱雅、赛诺菲、罗氏制药涨0.81%-0.20%。阿斯利康则收跌0.42%,葛兰素史克和雀巢至多跌2.16%,诺华制药跌3.85%。
金融界 · 02-27
【欧股“十一罗汉”|阿斯麦和LVMH集团收涨超2%,诺和诺德跌超2%】周三,阿斯麦控股荷兰阿姆斯特丹股价收涨2.39%,报714.50欧元。诺和诺德哥本哈根股价收跌2.16%,报642.80。LVMH集团涨2.35%,德国思爱普Sap涨1.03%,欧莱雅、赛诺菲、罗氏制药涨0.81%-0.20%。阿斯利康则收跌0.42%,葛兰素史克和雀巢至多跌2.16%,诺华制药跌3.85%。
【欧股“十一罗汉”|阿斯麦收跌2.2%,Hims减肥药业务前景提振诺和诺德收涨约2.8%】 周二,阿斯麦控股荷兰阿姆斯特丹股价收跌2.20%,报697.80欧元。诺和诺德哥本哈根股价收涨2.78%,报657.00,美国平价减肥药供应商Hims & Hers Health停售某些减肥药。诺华制药与葛兰素史克至多涨2.35%,雀巢和阿斯利康至多涨1.41%,赛诺菲和罗氏制药至多涨行0.7%,欧莱雅收平,德国思爱普Sap则收跌0.69%,LVMH集团跌1.14%。
金融界 · 02-26
【欧股“十一罗汉”|阿斯麦收跌2.2%,Hims减肥药业务前景提振诺和诺德收涨约2.8%】 周二,阿斯麦控股荷兰阿姆斯特丹股价收跌2.20%,报697.80欧元。诺和诺德哥本哈根股价收涨2.78%,报657.00,美国平价减肥药供应商Hims & Hers Health停售某些减肥药。诺华制药与葛兰素史克至多涨2.35%,雀巢和阿斯利康至多涨1.41%,赛诺菲和罗氏制药至多涨行0.7%,欧莱雅收平,德国思爱普Sap则收跌0.69%,LVMH集团跌1.14%。
【欧股“十一罗汉”|诺和诺德收涨超1.4%,阿斯麦涨约0.5%】周一,阿斯麦控股荷兰阿姆斯特丹股价收涨0.48%,报713.50欧元。诺和诺德哥本哈根股价收涨1.46%,报639.20。雀巢收涨3.15%,葛兰素史克涨1.65%,阿斯利康、欧莱雅、诺华、德国思爱普Sap涨0.55%-0.26%。罗氏制药和赛诺菲则至多收跌0.71%,LVMH集团跌1.47%。此外,欧洲芯片概念股普跌,BE半导体实业收跌2.17%,英飞凌、意法半导体至多跌1.29%,德国爱思强则涨1.76%。
金融界 · 02-25
【欧股“十一罗汉”|诺和诺德收涨超1.4%,阿斯麦涨约0.5%】周一,阿斯麦控股荷兰阿姆斯特丹股价收涨0.48%,报713.50欧元。诺和诺德哥本哈根股价收涨1.46%,报639.20。雀巢收涨3.15%,葛兰素史克涨1.65%,阿斯利康、欧莱雅、诺华、德国思爱普Sap涨0.55%-0.26%。罗氏制药和赛诺菲则至多收跌0.71%,LVMH集团跌1.47%。此外,欧洲芯片概念股普跌,BE半导体实业收跌2.17%,英飞凌、意法半导体至多跌1.29%,德国爱思强则涨1.76%。
阿斯利康(AZN.US)PD-L1+CTLA-4组合在华申报上市 一线治疗NSCLC
智通财经 · 02-21
阿斯利康(AZN.US)PD-L1+CTLA-4组合在华申报上市 一线治疗NSCLC
金十数据整理:每日美股市场要闻速递(2月20日 周四)
美港电讯 · 02-20
金十数据整理:每日美股市场要闻速递(2月20日 周四)
阿斯利康将以约1.6亿美元收购珐博进中国,并获得罗沙司他在中国的独家权利
美通社 · 02-20
阿斯利康将以约1.6亿美元收购珐博进中国,并获得罗沙司他在中国的独家权利
阿斯利康将以约1.6亿美元收购珐博进中国,并获得罗沙司他在中国的独家权利
美港电讯 · 02-20
阿斯利康将以约1.6亿美元收购珐博进中国,并获得罗沙司他在中国的独家权利
暂无数据
公司概况
公司名称:
阿斯利康
所属市场:
NASDAQ
上市日期:
--
主营业务:
阿斯利康股份有限公司于1992年6月17日根据1985年《公司法》在英格兰和威尔士注册成立。该公司是在1993年将Imperial化学工业公司的制药、农化和特种化学品业务分拆时成立的。1999年,公司出售了特种化学品业务。同样在1999年,该公司与瑞典Astra公司合并。2000年,该公司将农化业务分拆,并将其与诺华公司的同类业务合并,成立了一家新的公司Syngenta AG。2007年,集团收购了位于美国的生物制剂和疫苗企业MedImmune。2021年,集团收购了位于美国的罕见病企业Alexion。
发行价格:
--
{"stockData":{"symbol":"AZN","market":"US","secType":"STK","nameCN":"阿斯利康","latestPrice":75.99,"timestamp":1741636800000,"preClose":77.5,"halted":0,"volume":6254739,"hourTrading":{"tag":"盘后","latestPrice":75.94,"preClose":75.99,"latestTime":"19:57 EDT","volume":102353,"amount":7777745.9566,"timestamp":1741651036892},"delay":0,"floatShares":3089400894,"shares":3101214350,"eps":2.25,"marketStatus":"未开盘","change":-1.51,"latestTime":"03-10 16:00:00 EDT","open":76.11,"high":76.965,"low":75.47,"amount":477546633.11223,"amplitude":0.01929,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.25,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1741680000000},"marketStatusCode":0,"adr":1,"adrRate":0.5,"listingDate":737179200000,"exchange":"NASDAQ","adjPreClose":77.5,"dividendRate":0.020397,"preHourTrading":{"tag":"盘前","latestPrice":76.12,"preClose":77.5,"latestTime":"09:29 EDT","volume":176994,"amount":13499353.619280001,"timestamp":1741613399999},"postHourTrading":{"tag":"盘后","latestPrice":75.94,"preClose":75.99,"latestTime":"19:57 EDT","volume":102353,"amount":7777745.9566,"timestamp":1741651036892},"volumeRatio":1.068975,"impliedVol":0.2746,"impliedVolPercentile":0.724},"requestUrl":"/m/hq/s/AZN/tweets","defaultTab":"tweets","newsList":[{"id":"2518208405","title":"【欧股“十一罗汉”|诺和诺德跌超8%,阿斯麦跌超4%】周一,阿斯麦控股荷兰阿姆斯特丹股价收跌4.05%,报639.00欧元。诺和诺德哥本哈根股价收跌8.07%,报549.40丹麦克朗,为2023年8月7日以来首次收盘跌穿600整数位心理关口。德国思爱普Sap跌4.78%,阿斯利康跌1.91%,LVMH集团和赛诺菲至多收跌0.69%。罗氏制药、诺华制药、雀巢则至多收涨0.87%,欧莱雅涨1.38%,葛兰素史克涨1.6%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2518208405","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518208405?lang=zh_cn&edition=full","pubTime":"2025-03-11 01:02","pubTimestamp":1741626170,"startTime":"0","endTime":"0","summary":"周一,阿斯麦控股荷兰阿姆斯特丹股价收跌4.05%,报639.00欧元。诺和诺德哥本哈根股价收跌8.07%,报549.40丹麦克朗,为2023年8月7日以来首次收盘跌穿600整数位心理关口。德国思爱普Sap跌4.78%,阿斯利康跌1.91%,LVMH集团和赛诺菲至多收跌0.69%。罗氏制药、诺华制药、雀巢则至多收涨0.87%,欧莱雅涨1.38%,葛兰素史克涨1.6%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/11010248641321.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1191","IE00BD6J9T35.USD","LU0823434740.USD","LU0109394709.USD","BK4599","NVO","LU0154236417.USD","LU0320765992.SGD","LU2456880835.USD","BK4212","AZN","LU1734074674.USD","LU0345774631.USD","IE0002141913.USD","ASML","LU0097036916.USD","BK4568","LU2236285917.USD","IE00BJJMRZ35.SGD","NVS","BK4543","LU1093756168.USD","LU0211331839.USD","GSK","BK4532","LRLCY","IE00BKVL7J92.USD","IE00BFTCPJ56.SGD","LU0823434583.USD","NSRGY","GSK.UK","LU2063271972.USD","BK4588","LU1829250122.USD","IE0009355771.USD","BK4585","BK4578","BK4147","IE00B4R5TH58.HKD","BK4007","01477","LU2417539215.USD","03165","LU1093756325.SGD","LU0345774391.USD","LU0889565916.HKD","LU2462157665.USD","BK4183","IE0004445239.USD","BK1574"],"gpt_icon":0},{"id":"2518248700","title":"阿斯利康PD-L1肿瘤药在中国获批第四项适应证","url":"https://stock-news.laohu8.com/highlight/detail?id=2518248700","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518248700?lang=zh_cn&edition=full","pubTime":"2025-03-10 18:01","pubTimestamp":1741600887,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["PD","ALK","BK4588","LU0109394709.USD","LU1169590202.USD","BK4023","LU2236285917.USD","LU2456880835.USD","BK4007","LU0320765992.SGD","LU2462157665.USD","LU1169589451.USD","BK4568","LU1829250122.USD","LU0889565916.HKD","BK4500","AZN","BK4585","LU2417539215.USD","BK4008"],"gpt_icon":0},{"id":"2517438513","title":"阿斯利康(AZN.US)胃癌围手术期PD-L1联合疗法优于标准治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2517438513","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517438513?lang=zh_cn&edition=full","pubTime":"2025-03-07 21:20","pubTimestamp":1741353606,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,3月7日,阿斯利康宣布III期MATTERHORN研究结果显示,Imfinzi联合标准治疗FLOT化疗作为可切除的早期和局部晚期的胃癌和胃食管交界处癌患者围手术期治疗方案,主要终点无事件生存期具有统计学意义和临床意义的改善。MATTERHORN是首个证明免疫疗法联合治疗优于标准治疗的全球随机III期临床研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1259345.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2236285917.USD","BK4007","BK4585","PD","BK4568","BK4588","LU0109394709.USD","LU0320765992.SGD","LU1169589451.USD","LU1169590202.USD","LU0889565916.HKD","BK4023","LU1829250122.USD","LU2456880835.USD","LU2462157665.USD","AZN","LU2417539215.USD"],"gpt_icon":0},{"id":"2517448458","title":"医药生物行业专题:海外制药企业2024Q4&全年业绩回顾","url":"https://stock-news.laohu8.com/highlight/detail?id=2517448458","media":"国信证券股份有...","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517448458?lang=zh_cn&edition=full","pubTime":"2025-03-07 20:14","pubTimestamp":1741349673,"startTime":"0","endTime":"0","summary":"代谢:诺和诺德Ozempic+Wegovy+Rybelsus 2024年合计销售~293亿美元,礼来Mounjaro+Zepbound合计销售~165亿美元;美国降糖相关GLP-1总处方量增速15%+,2025年初减重GLP-1周度处方量较2024年初增长 ~3x。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307201454989fd3c6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307201454989fd3c6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B4R5TH58.HKD","LU1551013342.USD","LU1037948541.HKD","LU0912757837.SGD","LU0949170772.SGD","AMGN","LU0211328371.USD","LU0795875169.SGD","LU1093756168.USD","LU1267930573.SGD","LU1934455194.USD","BK4139","LLY","IE0004445239.USD","LU0820561909.HKD","AZN","LU1430594728.SGD","ABBV","LU0310799852.SGD","LU1003077747.HKD","LU2237443382.USD","LU2237443978.SGD","LU2468319806.SGD","BK4559","LU2237443549.SGD","LU0170899867.USD","LU0553294199.USD","LU0122379950.USD","IE00BFTCPJ56.SGD","LU0965509101.SGD","IE00BDGV0183.EUR","LU1267930490.SGD","LU1037948897.HKD","LU2237443622.USD","LU0985320562.USD","LU1291159041.SGD","LU1732799900.SGD","LU0738911758.USD","LU0965509283.SGD","LU1244550494.USD","LU1989772923.USD","LU1732800096.USD","LU1585245621.USD","LU1023059063.AUD","IE0002141913.USD","IE00B42XCP33.USD","LU0256863902.USD","BK4566","LU0256863811.USD","LU1496350502.SGD","LU1718418525.SGD","LU2237443465.HKD","LU1244550221.USD"],"gpt_icon":0},{"id":"2517477049","title":"【欧股“十一罗汉”|诺和诺德收涨约2.5%,阿斯麦涨超1.8%,雀巢则跌超1.8%】 周三,阿斯麦控股荷兰阿姆斯特丹股价收涨1.85%,报672.70欧元。诺和诺德哥本哈根股价收涨2.48%,报631.50。德国思爱普Sap收涨2.22%,欧莱雅涨1.79%,诺华制药涨0.62%。阿斯利康、罗氏制药、LVMH集团、赛诺菲则收跌0.02%-0.46%,葛兰素史克跌1.72%,雀巢跌1.83%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517477049","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517477049?lang=zh_cn&edition=full","pubTime":"2025-03-06 01:53","pubTimestamp":1741197233,"startTime":"0","endTime":"0","summary":"周三,阿斯麦控股荷兰阿姆斯特丹股价收涨1.85%,报672.70欧元。诺和诺德哥本哈根股价收涨2.48%,报631.50。德国思爱普Sap收涨2.22%,欧莱雅涨1.79%,诺华制药涨0.62%。阿斯利康、罗氏制药、LVMH集团、赛诺菲则收跌0.02%-0.46%,葛兰素史克跌1.72%,雀巢跌1.83%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/06015348550800.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU2456880835.USD","BK4588","NSRGY","LU2417539215.USD","IE0002141913.USD","BK4568","LU0154236417.USD","IE00BJJMRZ35.SGD","LU0823434740.USD","LU0345774631.USD","BK4578","BK1574","ASML","BK4599","AZN","IE00B4R5TH58.HKD","IE00BD6J9T35.USD","LU2236285917.USD","BK4007","IE0009355771.USD","LU0097036916.USD","IE00BZ1G4Q59.USD","NVO","GSK.UK","LU0345774391.USD","LU1093756168.USD","GSK","LU0211331839.USD","01477","LU0823434583.USD","BK1191","BK4212","IE0004445239.USD","IE00BJT1NW94.SGD","LRLCY","IE00BKVL7J92.USD","LU2462157665.USD","BK4543","LU0320765992.SGD","BK4147","LU0889565916.HKD","03165","NVS","IE00BFTCPJ56.SGD","LU1093756325.SGD","BK4532","BK4585","IE00B2B36J28.USD","LU0109394709.USD","LU1734074674.USD"],"gpt_icon":0},{"id":"2517111989","title":"第一三共/阿斯利康(AZN.US)重磅抗体偶联药物(ADC)Enhertu在3期临床试验中获得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2517111989","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517111989?lang=zh_cn&edition=full","pubTime":"2025-03-05 21:15","pubTimestamp":1741180517,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,阿斯利康和第一三共公司日前宣布,双方联合开发的重磅抗体偶联药物Enhertu,在3期临床试验DESTINY-Gastric04中获得积极结果。新闻稿表示,Enhertu是首个在随机3期临床试验中,作为二线疗法显著改善HER2阳性胃癌患者总生存期的HER2靶向疗法。新闻稿指出,转移性HER2阳性胃癌一线治疗出现疾病进展后,历史上在随机临床试验中,尚未有HER2靶向药物在二线治疗中展示出生存获益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258239.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0320765992.SGD","LU2456880835.USD","BK1576","BK4231","LU0109394709.USD","LU1829250122.USD","LU2417539215.USD","BK4588","ADC","BK4080","LU2462157665.USD","BK1583","BK1141","AZN","BK4568","BK4007","LU2236285917.USD","03347","LU0889565916.HKD","BK4585"],"gpt_icon":0},{"id":"2516626829","title":"阿斯利康(AZN)盘前升1.52% 重度哮喘治疗药物显示积极效果","url":"https://stock-news.laohu8.com/highlight/detail?id=2516626829","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516626829?lang=zh_cn&edition=full","pubTime":"2025-03-04 17:59","pubTimestamp":1741082382,"startTime":"0","endTime":"0","summary":"金吾财讯 | 阿斯利康(AZN)盘前股价走高,暂升1.52%,报77.26美元。消息面上,在近期于美国加州圣地亚哥举办的美国过敏、哮喘和免疫学会年会(AAAAI)上,阿斯利康一款用于重度哮喘治疗的药物特泽利尤单抗(Tezepelumab),在慢性鼻窦炎伴鼻息肉的治疗领域呈现出令人瞩目的积极效果。依据一项三期临床研究成果,特泽利尤单抗能够显著缓解慢性鼻窦炎伴鼻息肉患者的鼻塞症状,有效缩小息肉体积,近乎让患者无需进行手术治疗。这一最新研究数据已发表于《新英格兰医学杂志》,并以最新突破性研究口头报告的形式,在 2025 年 AAAAI 大会上予以发布。","market":"other","thumbnail":"https://static.szfiu.com/news/20210625/OGIwZDQyMDYwMGIwOWQ1NTkxMDE1Mzc1NTA2MDQ=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/OGIwZDQyMDYwMGIwOWQ1NTkxMDE1Mzc1NTA2MDQ=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"286019","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","AZN","LU0320765992.SGD","LU1829250122.USD","BK4007","LU0889565916.HKD","BK4585","LU2462157665.USD","BK4568","LU2236285917.USD","LU2417539215.USD","LU2456880835.USD","LU0109394709.USD"],"gpt_icon":0},{"id":"2516661606","title":"阿斯利康全球研发(中国)有限公司药品申请临床试验默示许可获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2516661606","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516661606?lang=zh_cn&edition=full","pubTime":"2025-03-04 12:18","pubTimestamp":1741061880,"startTime":"0","endTime":"0","summary":"3月4日,据CDE官网消息,阿斯利康全球研发(中国)有限公司、阿斯利康制药有限公司、上海合全医药有限公司联合申请药品“Ceralasertib薄膜包衣片”,获得临床试验默示许可,受理号CXHB2400299。阿斯利康全球研发(中国)有限公司,成立于2021年,位于上海市,是一家以从事研究和试验发展为主的企业。主要股东信息显示,阿斯利康全球研发(中国)有限公司由阿斯利康大陆有限公司 ASTRAZENECA CONTINENT B.V.持股100%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/04121848504570.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4007","BK4568","LU1829250122.USD","LU2236285917.USD","LU2462157665.USD","LU0109394709.USD","03347","BK1583","BK1141","BK4585","BK1576","AZN","LU0889565916.HKD","LU2417539215.USD","LU2456880835.USD","BK4588","LU0320765992.SGD"],"gpt_icon":0},{"id":"2516639334","title":"金十数据整理:每日美股市场要闻速递(3月3日 周一)","url":"https://stock-news.laohu8.com/highlight/detail?id=2516639334","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516639334?lang=zh_cn&edition=full","pubTime":"2025-03-03 21:54","pubTimestamp":1741010095,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["AMD","APT.USD.CC","BTC.USD.HKCC","TSLA","MSTU","GFS","AZN","09439","161631","HODL","SNX.USD.CC","BTCO","DOT.USD.HKCC","ON","ADC","TON.USD.HKCC","AVGO","AVAX.USD.HKCC","UNI.USD.HKCC","LDO.USD.HKCC","USDT.USD.CC","AAPL","09868","EZBC","FBTC","APT.USD.HKCC","NVDA","159813","ARKK","COMP.USD.HKCC","LTC.USD.HKCC","GBTC","BRRR","AVAX.USD.CC","MKR.USD.CC","SNX.USD.HKCC","03008","03042","JNJ","BABA","BTC.USD.CC","DEFI","BTCW","BITO","09042","XPEV","ATOM.USD.HKCC","ALGM","VBTC.AU"],"gpt_icon":1},{"id":"2516936572","title":"高盛将阿斯利康、诺和诺德、力拓纳入其欧洲“确信名单”。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516936572","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516936572?lang=zh_cn&edition=full","pubTime":"2025-03-03 13:59","pubTimestamp":1740981553,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU1668664300.SGD","IE0004086264.USD","LU2471134796.USD","BK4532","LU2237438978.USD","LU2237443622.USD","IE00B19Z3581.USD","LU2237443895.HKD","LU2237443549.SGD","LU0345780950.USD","LU2417539215.USD","IE00B3M56506.USD","LU0788109121.HKD","IE00BWDBJ516.SGD","IE00BZ1G4Q59.USD","LU0654597011.USD","BK4550","LU2750360997.AUD","LU1868837136.USD","BK4168","IE0034235188.USD","BK4533","AZN","LU0109394709.USD","IE0034235071.USD","LU0154236417.USD","NVO","RIO.UK","LU0505663152.USD","LU0096364046.USD","LU0955669360.SGD","LU2471134952.CNY","LU1023059493.AUD","LU1868836914.USD","LU0889565916.HKD","LU1868836591.USD","IE00BFXG1179.USD","LU0171293334.USD","IE00BSNM7G36.USD","LU2471134879.HKD","LU0345777147.USD","LU1130305938.SGD","LU2236285917.USD","RIO","LU1829250122.USD","BK4568","LU2237443465.HKD","IE00BKVL7J92.USD","LU1078025761.USD","BK4588"],"gpt_icon":0},{"id":"2516578625","title":"第一三共/阿斯利康(AZN.US)重磅ADC疗法有望再获欧盟批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2516578625","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516578625?lang=zh_cn&edition=full","pubTime":"2025-03-03 10:46","pubTimestamp":1740969968,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,日前,第一三共与阿斯利康共同宣布,其联合开发的重磅抗体偶联药物Enhertu获得欧洲药品管理局人用药品委员会推荐在欧盟获批,作为单药用于治疗不可切除或转移性激素受体阳性、HER2低表达或HER2极低表达的乳腺癌成人患者,这些患者至少接受过一种内分泌疗法治疗转移性癌症,且被认为不适合接受内分泌疗法作为下一线治疗。据悉,Enhertu是首款具有不限癌种适应症的HER2靶向ADC疗法。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1256744.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2456880835.USD","BK4231","LU0109394709.USD","BK4585","LU2236285917.USD","BK4080","AZN","BK4568","LU1829250122.USD","LU2417539215.USD","BK4588","LU2462157665.USD","LU0889565916.HKD","BK4007","ADC","LU0320765992.SGD"],"gpt_icon":0},{"id":"2514110800","title":"金十数据整理:每日美股行情要闻速递(2月27日周四)","url":"https://stock-news.laohu8.com/highlight/detail?id=2514110800","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514110800?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:02","pubTimestamp":1740664933,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["NVDA","USJW.SI","LU1983260115.SGD","EBAY","LU2065171402.SGD","03160","NVD","NVDD","NVDX","PSX","TM","TWmain","IE00BKVL7J92.USD","161631","TSM","HK0000320223.HKD","LU2237443549.SGD","CVX","09988","BABA","GOOGL","SG9999017495.SGD","03145","NVDU","LU1261432733.SGD","IE00BZ199S13.USD","LU2290526834.HKD","NVIW.SI","AAPL","LU1548497426.USD","AZN","NVDY","SNVD.UK","LU1551013342.USD","GOOG","LU1066051811.HKD","NVD2.UK","LU2028103732.USD","2NVD.UK","3NVD.UK","NVDS.UK","IE00B1BXHZ80.USD","NVD3.UK","NVDS","03347","MACW.SI","LU1582987324.SGD","EWT","NVDL"],"gpt_icon":1},{"id":"2514593844","title":"阿斯利康(AZN.US)口服小分子疗法3期临床试验结果积极","url":"https://stock-news.laohu8.com/highlight/detail?id=2514593844","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514593844?lang=zh_cn&edition=full","pubTime":"2025-02-27 14:01","pubTimestamp":1740636060,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,2月27日,阿斯利康宣布,3期临床试验SERENA-6的中期分析显示,其在研口服选择性雌激素受体降解剂camizestrant与CDK4/6抑制剂联用,在主要终点无进展生存期上显示出统计学显著且具有临床意义的改善。据了解,SERENA-6是首个采用循环肿瘤DNA检测,发现肿瘤内分泌耐药性的出现并在疾病进展前提示治疗转换的全球性3期临床试验。Camizestrant是一种效力强劲的新一代口服SERD及雌激素受体完全拮抗剂,目前正在3期试验中接受评估,用于治疗HR阳性乳腺癌。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1255131.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","BK4568","LU1829250122.USD","LU2236285917.USD","LU2462157665.USD","LU0109394709.USD","03347","BK1583","BK1141","BK4585","BK1576","AZN","LU0889565916.HKD","LU2417539215.USD","LU2456880835.USD","BK4588","LU0320765992.SGD"],"gpt_icon":0},{"id":"2514695998","title":"【欧股“十一罗汉”|阿斯麦和LVMH集团收涨超2%,诺和诺德跌超2%】周三,阿斯麦控股荷兰阿姆斯特丹股价收涨2.39%,报714.50欧元。诺和诺德哥本哈根股价收跌2.16%,报642.80。LVMH集团涨2.35%,德国思爱普Sap涨1.03%,欧莱雅、赛诺菲、罗氏制药涨0.81%-0.20%。阿斯利康则收跌0.42%,葛兰素史克和雀巢至多跌2.16%,诺华制药跌3.85%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514695998","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514695998?lang=zh_cn&edition=full","pubTime":"2025-02-27 02:33","pubTimestamp":1740594799,"startTime":"0","endTime":"0","summary":"周三,阿斯麦控股荷兰阿姆斯特丹股价收涨2.39%,报714.50欧元。诺和诺德哥本哈根股价收跌2.16%,报642.80。LVMH集团涨2.35%,德国思爱普Sap涨1.03%,欧莱雅、赛诺菲、罗氏制药涨0.81%-0.20%。阿斯利康则收跌0.42%,葛兰素史克和雀巢至多跌2.16%,诺华制药跌3.85%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/27023348414142.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU0889565916.HKD","NSRGY","NVO","BK4147","BK4007","LU1734074674.USD","LU2462157665.USD","LU0109394709.USD","GSK.UK","LU0320765992.SGD","LU2236285917.USD","IE0002141913.USD","LU0097036916.USD","BK4599","LU2417539215.USD","LU1829250122.USD","IE0004445239.USD","LU0823434740.USD","ASML","IE00BJJMRZ35.SGD","IE00BZ1G4Q59.USD","BK4543","LU2456880835.USD","LU1093756168.USD","IE00BKVL7J92.USD","LU0211331839.USD","03165","AZN","IE00BJT1NW94.SGD","BK4212","NVS","GSK","01477","LU0154236417.USD","BK1574","LU0823434583.USD","LU2063271972.USD","IE00B2B36J28.USD","IE00BD6J9T35.USD","LU1093756325.SGD","BK4568","IE00BFTCPJ56.SGD","BK1191","BK4585","BK4588","BK4183","IE0009355771.USD","IE00B4R5TH58.HKD","BK4532","LRLCY"],"gpt_icon":0},{"id":"2514950017","title":"【欧股“十一罗汉”|阿斯麦收跌2.2%,Hims减肥药业务前景提振诺和诺德收涨约2.8%】 周二,阿斯麦控股荷兰阿姆斯特丹股价收跌2.20%,报697.80欧元。诺和诺德哥本哈根股价收涨2.78%,报657.00,美国平价减肥药供应商Hims & Hers Health停售某些减肥药。诺华制药与葛兰素史克至多涨2.35%,雀巢和阿斯利康至多涨1.41%,赛诺菲和罗氏制药至多涨行0.7%,欧莱雅收平,德国思爱普Sap则收跌0.69%,LVMH集团跌1.14%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514950017","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514950017?lang=zh_cn&edition=full","pubTime":"2025-02-26 01:54","pubTimestamp":1740506070,"startTime":"0","endTime":"0","summary":"周二,阿斯麦控股荷兰阿姆斯特丹股价收跌2.20%,报697.80欧元。诺和诺德哥本哈根股价收涨2.78%,报657.00,美国平价减肥药供应商Hims & Hers Health停售某些减肥药。诺华制药与葛兰素史克至多涨2.35%,雀巢和阿斯利康至多涨1.41%,赛诺菲和罗氏制药至多涨行0.7%,欧莱雅收平,德国思爱普Sap则收跌0.69%,LVMH集团跌1.14%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/26015448386051.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU1734074674.USD","IE00BZ1G4Q59.USD","BK4212","IE00B2B36J28.USD","IE00BJT1NW94.SGD","BK1574","AZN","IE00BFTCPJ56.SGD","LU2063271972.USD","BK4599","BK4007","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","GSK.UK","LU1093756325.SGD","BK4578","ASML","LU0211331839.USD","LU0109394709.USD","IE0002141913.USD","LU1093756168.USD","LU0320765992.SGD","BK4183","03165","LU1829250122.USD","LU0889565916.HKD","GSK","LU2417539215.USD","IE00BD6J9T35.USD","BK4532","BK4585","LU2236285917.USD","LU0097036916.USD","IE0009355771.USD","NVO","BK4568","BK4543","01477","BK1191","IE0004445239.USD","LU2456880835.USD","LU0154236417.USD","LU2462157665.USD","BK4147","LU0823434583.USD","LU0823434740.USD","LRLCY","IE00BKVL7J92.USD","NSRGY","NVS"],"gpt_icon":0},{"id":"2514666774","title":"【欧股“十一罗汉”|诺和诺德收涨超1.4%,阿斯麦涨约0.5%】周一,阿斯麦控股荷兰阿姆斯特丹股价收涨0.48%,报713.50欧元。诺和诺德哥本哈根股价收涨1.46%,报639.20。雀巢收涨3.15%,葛兰素史克涨1.65%,阿斯利康、欧莱雅、诺华、德国思爱普Sap涨0.55%-0.26%。罗氏制药和赛诺菲则至多收跌0.71%,LVMH集团跌1.47%。此外,欧洲芯片概念股普跌,BE半导体实业收跌2.17%,英飞凌、意法半导体至多跌1.29%,德国爱思强则涨1.76%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514666774","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514666774?lang=zh_cn&edition=full","pubTime":"2025-02-25 01:50","pubTimestamp":1740419418,"startTime":"0","endTime":"0","summary":"周一,阿斯麦控股荷兰阿姆斯特丹股价收涨0.48%,报713.50欧元。诺和诺德哥本哈根股价收涨1.46%,报639.20。雀巢收涨3.15%,葛兰素史克涨1.65%,阿斯利康、欧莱雅、诺华、德国思爱普Sap涨0.55%-0.26%。罗氏制药和赛诺菲则至多收跌0.71%,LVMH集团跌1.47%。此外,欧洲芯片概念股普跌,BE半导体实业收跌2.17%,英飞凌、意法半导体至多跌1.29%,德国爱思强则涨1.76%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"be3201d4ba339139b8fa1c56337988b2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/25015048358625.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU0823434740.USD","NVS","AZN","IE00B2B36J28.USD","01477","BK4147","LU2417539215.USD","LU0444973449.USD","BE","BK4141","159582","IE00BMPRXN33.USD","GSK","LU2236285917.USD","LU1093756168.USD","BK4605","159813","LU1815336760.USD","IE00BJJMRZ35.SGD","LU0823434583.USD","03165","LU2294711713.HKD","IE0004445239.USD","LU0097036916.USD","LU2506951792.HKD","NVO","LU0211331839.USD","LU2063271972.USD","BK4212","LU0109394709.USD","BK4541","LU1093756325.SGD","LRLCY","IE00BD6J9T35.USD","IE00BJT1NW94.SGD","BK4585","ASML","BK4568","IE00BZ1G4Q59.USD","LU1642822529.SGD","BK4578","BK4554","BK4599","NSRGY","GSK.UK","BK4007","IE00BFTCPJ56.SGD","BK4182","STM","LU1829250122.USD"],"gpt_icon":0},{"id":"2513606242","title":"阿斯利康(AZN.US)PD-L1+CTLA-4组合在华申报上市 一线治疗NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2513606242","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513606242?lang=zh_cn&edition=full","pubTime":"2025-02-21 21:24","pubTimestamp":1740144275,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,2月21日,CDE网站显示,阿斯利康(AZN.US)的PD-L1单抗度伐利尤单抗在华申报新适应症。根据阿斯利康2024年财报,此次申报的适应症为联合替西木单抗和标准治疗一线治疗无致敏表皮生长因子受体(EGFR)突变或间变性淋巴瘤激酶(ALK)基因组肿瘤畸变的转移性非小细胞肺癌(NSCLC)成年患者。此次上市申请是基于III期POSEIDON研究的积极结果。该研究在1013例EGFR/ALK野生型转移性NSCLC患者中评估了度伐利尤单抗(1500mg)+替西木单抗(75mg)±标准治疗(铂类化疗)对比标准治疗的疗效和安全性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1253018.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AZN","LU2462157665.USD","BK4007","PD","BK4585","LU0889565916.HKD","BK4568","LU0320765992.SGD","BK4588","LU2456880835.USD","LU1169590202.USD","LU2236285917.USD","LU2417539215.USD","LU1169589451.USD","BK4023","LU1829250122.USD","LU0109394709.USD"],"gpt_icon":0},{"id":"2512447069","title":"金十数据整理:每日美股市场要闻速递(2月20日 周四)","url":"https://stock-news.laohu8.com/highlight/detail?id=2512447069","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512447069?lang=zh_cn&edition=full","pubTime":"2025-02-20 21:43","pubTimestamp":1740059026,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU0354030511.USD","LU1917777945.USD","LU0979878070.USD","LU1935043536.SGD","GDS","LU1935042991.SGD","LU1119994496.HKD","IE0034235303.USD","LU1206713676.USD","LU1868836757.USD","WMT","IE0004445239.USD","LU2360106780.USD","RIO.UK","LU0823434740.USD","LU0879622024.SGD","LU0052756011.USD","LU1880383366.USD","RIO","LU0505663152.USD","LU0106261372.USD","MSFT","AZN","LU0965508806.USD","BK1104","LU0061475181.USD","LU0889565916.HKD","09626","LU0689626769.HKD","AAPL","LU1242518931.SGD","SG9999001143.SGD","09988","LU0985320562.USD","LU0823417737.USD","LU0128525689.USD","BK1588","LU0683600562.USD","IE00BN29S564.USD","LU0077335932.USD","BABA","MACW.SI","SG9999015978.USD","LU0823417653.USD","LU2111349929.HKD","09698","LU2279689827.SGD","BILI","HK0000320223.HKD","LU0061474705.USD"],"gpt_icon":0},{"id":"2512844007","title":"阿斯利康将以约1.6亿美元收购珐博进中国,并获得罗沙司他在中国的独家权利","url":"https://stock-news.laohu8.com/highlight/detail?id=2512844007","media":"美通社","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512844007?lang=zh_cn&edition=full","pubTime":"2025-02-20 21:18","pubTimestamp":1740057480,"startTime":"0","endTime":"0","summary":"根据协议条款,珐博进将获得8500万美元的企业价值,以及交易交割时珐博进中国持有的约7500万美元现金,总计约1.6亿美元。完成交割后,阿斯利康将获得罗沙司他在中国的所有权利。珐博进保留其在美国及未授权给安斯泰来的市场对罗沙司他的权利。\"我们很高兴收购珐博进中国,并获得罗沙司他在中国的所有权利,进一步充实我们在中国的现有产品组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4623619_ZH23619_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0320765992.SGD","LU2236285917.USD","LU0109394709.USD","BK4007","LU2456880835.USD","LU2462157665.USD","AZN","LU0889565916.HKD","BK4585","BK4568","LU1829250122.USD","LU2417539215.USD","BK4588"],"gpt_icon":0},{"id":"2512744479","title":"阿斯利康将以约1.6亿美元收购珐博进中国,并获得罗沙司他在中国的独家权利","url":"https://stock-news.laohu8.com/highlight/detail?id=2512744479","media":"美港电讯","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512744479?lang=zh_cn&edition=full","pubTime":"2025-02-20 21:02","pubTimestamp":1740056549,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU2462157665.USD","LU0889565916.HKD","LU2456880835.USD","BK4585","LU0320765992.SGD","BK4588","BK4568","LU2236285917.USD","LU2417539215.USD","BK4007","LU1829250122.USD","LU0109394709.USD","AZN"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.astrazeneca.com","stockEarnings":[{"period":"1week","weight":-0.0014},{"period":"1month","weight":0.0556},{"period":"3month","weight":0.1311},{"period":"6month","weight":-0.0564},{"period":"1year","weight":0.1427},{"period":"ytd","weight":0.1598}],"compareEarnings":[{"period":"1week","weight":-0.0397},{"period":"1month","weight":-0.0669},{"period":"3month","weight":-0.07},{"period":"6month","weight":0.0111},{"period":"1year","weight":0.0955},{"period":"ytd","weight":-0.0435}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"阿斯利康股份有限公司于1992年6月17日根据1985年《公司法》在英格兰和威尔士注册成立。该公司是在1993年将Imperial化学工业公司的制药、农化和特种化学品业务分拆时成立的。1999年,公司出售了特种化学品业务。同样在1999年,该公司与瑞典Astra公司合并。2000年,该公司将农化业务分拆,并将其与诺华公司的同类业务合并,成立了一家新的公司Syngenta AG。2007年,集团收购了位于美国的生物制剂和疫苗企业MedImmune。2021年,集团收购了位于美国的罕见病企业Alexion。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.001428},{"month":2,"riseRate":0.40625,"avgChangeRate":-0.017129},{"month":3,"riseRate":0.5625,"avgChangeRate":0.029013},{"month":4,"riseRate":0.677419,"avgChangeRate":0.03301},{"month":5,"riseRate":0.516129,"avgChangeRate":0.008567},{"month":6,"riseRate":0.46875,"avgChangeRate":0.020173},{"month":7,"riseRate":0.59375,"avgChangeRate":-0.004027},{"month":8,"riseRate":0.46875,"avgChangeRate":0.002026},{"month":9,"riseRate":0.5625,"avgChangeRate":0.002514},{"month":10,"riseRate":0.53125,"avgChangeRate":0.013465},{"month":11,"riseRate":0.5,"avgChangeRate":-0.000033},{"month":12,"riseRate":0.5625,"avgChangeRate":0.007964}],"exchange":"NASDAQ","name":"阿斯利康","nameEN":"AstraZeneca PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.31.5","shortVersion":"4.31.5","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阿斯利康,AZN,阿斯利康股票,阿斯利康股票老虎,阿斯利康股票老虎国际,阿斯利康行情,阿斯利康股票行情,阿斯利康股价,阿斯利康股市,阿斯利康股票价格,阿斯利康股票交易,阿斯利康股票购买,阿斯利康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}